Evidence map›Paper›PMID 37156649›Full record

ReviewTrends in biochemical sciences2023

Tudor-dimethylarginine interactions: the condensed version.

Daniela Šimčíková, Sara Gelles-Watnick, Karla M Neugebauer

Open access · greenAbstract readReview
In one paragraph

Review in Trends in biochemical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Protein arginine methylation in transcription and epigenetic regulation.Frontiers in epigenetics and epigenomics · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Daniela ŠimčíkováDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA.
Sara Gelles-WatnickDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA.
Karla M NeugebauerDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA. Electronic address: karla.neugebauer@yale.edu.
Yale University · US

Funding

DMA-Tudor interaction modules: a novel approach to Survival Motor Neuron protein (SMN) and Cajal body functionR01NS128358 · NINDS · YALE UNIVERSITY · PI Karla M Neugebauer · 2022 to 2026
$2.2M
NINDS NIH HHS R01 NS128358
6 · The paper itself

Abstract

Biomolecular condensates (BMCs) can facilitate or inhibit diverse cellular functions. BMC formation is driven by noncovalent protein-protein, protein-RNA, and RNA-RNA interactions. Here, we focus on Tudor domain-containing proteins - such as survival motor neuron protein (SMN) - that contribute to BMC formation by binding to dimethylarginine (DMA) modifications on protein ligands. SMN is present in RNA-rich BMCs, and its absence causes spinal muscular atrophy (SMA). SMN's Tudor domain forms cytoplasmic and nuclear BMCs, but its DMA ligands are largely unknown, highlighting open questions about the function of SMN. Moreover, DMA modification can alter intramolecular interactions and affect protein localization. Despite these emerging functions, the lack of direct methods of DMA detection remains an obstacle to understanding Tudor-DMA interactions in cells.

Indexed as

RNARNA-Binding ProteinsArginineLigandsSMN Complex ProteinsArgininedimethylarginineLigandsRNARNA-Binding ProteinsSMN Complex Proteinsbiomolecular condensatedimethylarginineribonucleoprotein particleSMN proteinspinal muscular atrophyTudor domain

Identifiers

PMID37156649
PMCPMC10524826
OpenAlexW4372316623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.